Lupin has got the US health regulator’s approval to market Fyavolv tablets that are used in the treatment of postmenopausal osteoporosis, in the American market.

Lupin said in a statement that the company has received the final approval from the United States Food and Drug Administration (FDA) to market Fyavolv tablets.

It further added that “Lupin’s US subsidiary, Lupin Pharmaceuticals Inc shall commence promoting the production in the US shortly.

Read EquityPandit’s Nifty Pharma Outlook for this week